Publication date: Available online 19 October 2017
Source:Bioorganic & Medicinal Chemistry
Author(s): Amanda R. Aldous, Jesse Z. Dong
Neoantigens arise from somatic mutations that differ from wild-type antigens and are specific to each individual patient, which maximizes the number of tumor specific targets and immune responses. Decades of work has increasingly shown the potential of targeting neoantigens to generate effective clinical responses. Current clinical trials using neoantigen targeting cancer vaccines, including in combination with checkpoint blockade monoclonal antibodies, have observed potent T-cell response against those neoantigens accompanied by tumor regression in patients. Therefore, personalized peptide-based neoantigen vaccines have become a promising approach toward cancer immunotherapy.
Graphical abstract
http://ift.tt/2yuMRbD
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου